Vanda Pharmaceuticals had 9% revenue growth and heavy losses with a 1.4x sales valuation and a PDUFA date. Check out why VNDA stock is downgraded to hold.
Stocktwits on MSN
Vanda stock draws heavy buzz ahead of FDA verdict on Bysanti for bipolar, schizophrenia
The FDA has set a Feb. 21 target decision on the Bysanti NDA. ・Vanda submitted the NDA in March 2025 for Bysanti to treat acute bipolar I disorder and schizophrenia. ・In May, the FDA said the ...
By Danuta Radzik On October 30, 2025, two DDL shareholders, Danuta Radzik and Vanda Radzik, the Greenheart Movement and other ...
In the lead-up to the inaugural sailing of Disney Adventure from Singapore on 10 March, Marina Bay precinct partners UOB, Marina Bay Sands and Singapore Tourism Board, together with Disney Cruise Line ...
Recently published Phenylketonuria Market Insights report includes a comprehensive understanding of current treatment practices, phenylketonuria emerging drugs, market share of individual therapies, ...
NGGT002 (NGGT), JNT-517 (Jnana Therapeutics), Pegvaliase (BioMarin), and others under investigation, the phenylketonuria ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results